Spark Therapeutics to Host Conference Call on Wednesday, Feb. 22 at 8:30 a.m. to Discuss 2016 Results
February 15 2017 - 7:30AM
Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy
company dedicated to challenging the inevitability of genetic
disease, will host a conference call on Wednesday, Feb. 22, 2017,
at 8:30 a.m. EST to discuss corporate and financial results for the
year that ended Dec. 31, 2016.
The call can be accessed by dialing (855) 851-4526 (domestic) or
(720) 634-2901 (international), and entering passcode 69899623. To
access a live audio webcast, please visit the “Investors” section
at www.sparktx.com.
A replay of the call will be available for one week following
the call and can be accessed by dialing (855) 859-2056 (domestic)
or (404) 537-3406 (international), and entering passcode 69899623,
or by visiting the “Investors” section at www.sparktx.com.
About Spark TherapeuticsSpark Therapeutics, a
fully integrated company, strives to challenge the inevitability of
genetic disease by discovering, developing, and delivering gene
therapies that address inherited retinal diseases (IRDs),
neurodegenerative diseases, as well as diseases that can be
addressed by targeting the liver. Our validated platform
successfully has delivered proof-of-concept data with
investigational gene therapies in the retina and liver. Our most
advanced investigational candidate, voretigene neparvovec, in
development for the treatment of biallelic RPE65-mediated IRD, has
received orphan designations in the U.S. and European Union, and
breakthrough therapy designation in the U.S. The pipeline also
includes SPK-7001 in a Phase 1/2 trial for choroideremia, and two
hemophilia development programs: SPK-9001 (which also has received
both breakthrough therapy and orphan product designations) in a
Phase 1/2 trial for hemophilia B being developed in collaboration
with Pfizer, and SPK-8011, in a Phase 1/2 trial for hemophilia A to
which Spark Therapeutics retains global commercialization rights.
To learn more about us and our growing pipeline, visit
www.sparktx.com.
Investor Contact:
Ryan Asay
Ryan.asay@sparktx.com
(215) 239-6424
Media Contact:
Monique da Silva
Monique.dasilva@sparktx.com
215-282-7470
Onconetix (NASDAQ:ONCE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Onconetix (NASDAQ:ONCE)
Historical Stock Chart
From Apr 2023 to Apr 2024